Evidence map›Paper›PMID 24998941›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2014

Ocular delivery of macromolecules.

Yoo Chun Kim, Bryce Chiang, Xianggen Wu, Mark R Prausnitz

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
19.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it, 228 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Yoo Chun KimSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.
Bryce ChiangWallace Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Georgia Institute of Technology, Atlanta, GA 30332, USA.
Xianggen WuSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA; State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong Academy of Medical Sciences, Qingdao 266071, China.
Mark R PrausnitzSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA; Wallace Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Georgia Institute of Technology, Atlanta, GA 30332, USA. Electronic address: prausnitz@gatech.edu.
The Wallace H. Coulter Department of Biomedical Engineering · USGeorgia Institute of Technology · USShandong Eye Hospital · CN

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
P30-Core Grant for Vision Research Core CP30EY006360 · NEI · EMORY UNIVERSITY · PI GROSSNIKLAUS, HANS E. · 1986 to 2025
$15.3M
Transscleral Drug Delivery for Retinal DisordersR24EY017045 · NEI · EMORY UNIVERSITY · PI EDELHAUSER, HENRY FRANCIS · 2006 to 2010
$6.9M
VIsion Science Training in AtlantaT32EY007092 · NEI · EMORY UNIVERSITY · PI Machelle T. Pardue · 1985 to 2026
$4.6M
Suprachroidal Drug Delivery for Retina DisordersR01EY022097 · NEI · UNIVERSITY OF COLORADO DENVER · PI KOMPELLA, UDAY B, PRAUSNITZ, MARK R. · 2013 to 2016
$2.3M
Pharmacokinetics of Suprachoroidal Delivering using MicroneedlesF30EY025154 · NEI · EMORY UNIVERSITY · PI CHIANG, BRYCE · 2015 to 2018
$158k
NEI NIH HHS F30 EY025154NEI NIH HHS P30 EY006360NEI NIH HHS R01 EY022097NEI NIH HHS R01-EY022097NEI NIH HHS R24 EY017045NEI NIH HHS R24-EY017045NEI NIH HHS T32 EY007092NIGMS NIH HHS T32 GM008169
6 · The paper itself

Abstract

Biopharmaceuticals are making increasing impact on medicine, including treatment of indications in the eye. Macromolecular drugs are typically given by physician-administered invasive delivery methods, because non-invasive ocular delivery methods, such as eye drops, and systemic delivery, have low bioavailability and/or poor ocular targeting. There is a need to improve delivery of biopharmaceuticals to enable less-invasive delivery routes, less-frequent dosing through controlled-release drug delivery and improved drug targeting within the eye to increase efficacy and reduce side effects. This review discusses the barriers to drug delivery via various ophthalmic routes of administration in the context of macromolecule delivery and discusses efforts to develop controlled-release systems for delivery of biopharmaceuticals to the eye. The growing number of macromolecular therapies in the eye needs improved drug delivery methods that increase drug efficacy, safety and patient compliance.

Indexed as

Administration, OphthalmicDelayed-Action PreparationsDrug Delivery SystemsInjections, IntraocularBiological AvailabilityDrug CarriersHumansMacromolecular SubstancesOphthalmic SolutionsPolymersDelayed-Action PreparationsDrug CarriersMacromolecular SubstancesOphthalmic SolutionsPolymersBarriersControlled releaseDrug deliveryEyeMacromoleculesTargeting

Identifiers

PMID24998941
PMCPMC4142116
OpenAlexW2168009513

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.